Abstract
Objective: Immunotherapy with checkpoint inhibitors has revolutionized treatment of advanced cancers. Characterizing biomarkers that predict response to this therapeutic approach is important, as these therapies can have significant toxicities. In some tumor types, such as melanoma, higher numbers of tumor-infiltrating lymphocytes are associated with improved response. For endometrial cancer, mismatch repair deficiency is associated with higher numbers of tumor-associated lymphocytes and better response to checkpoint inhibition.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
